Chongqing Zhifei Biological Products (300122.SZ): HK.3-JN.1 COVID-19 mRNA vaccine approved for clinical trials.

15:46 26/02/2026

Chifeng Biotech (300122.SZ) announced that its wholly-owned subsidiary, Anhui Chifeng Longke Ma Biopharmaceutical Co., Ltd., recently reported that the HK.3-JN.1, a novel coronavirus mRNA vaccine independently developed by Chifeng Longke Ma, has received the National Medical Products Administration's approval for clinical trials, allowing the product to conduct clinical trials for preventing diseases caused by novel coronavirus infections.

Chongqing Zhifei Biological Products(300122.SZ) Announcement: The company received a report from its wholly-owned subsidiary Anhui Zhifei Longmai Biopharmaceutical Co., Ltd., stating that the HK.3-JN.1 novel coronavirus mRNA vaccine independently developed by Zhifei Longmai has obtained the approval notice from the National Medical Products Administration for conducting clinical trials for preventing diseases caused by novel coronavirus infections.

CLOUD FACTORY (02512): Zhu Wentao resigns as an executive director of the company.

GREENHEART GP (00094) issues a profit warning, expecting a net loss reduction of no less than 45% year-on-year in 2025.

Citigroup: CLP Holdings (00002) full-year profit falls short of expectations, profits from Australian operations plummeted by more than 80%.

CLOUD FACTORY (02512): Zhu Wentao resigns as an executive director of the company.

GREENHEART GP (00094) issues a profit warning, expecting a net loss reduction of no less than 45% year-on-year in 2025.

Citigroup: CLP Holdings (00002) full-year profit falls short of expectations, profits from Australian operations plummeted by more than 80%.